key: cord-0078547-n2es09g1
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: COVID-19 and Light Chain Amyloidosis: Correspondence
date: 2022-05-24
journal: Am J Med
DOI: 10.1016/j.amjmed.2022.02.004
sha: 529597c51b5dd83f54d636662dcf36b7a0f5ab50
doc_id: 78547
cord_uid: n2es09g1

nan

To the Editor:

We would like to discuss the article "COVID-19 and Light Chain Amyloidosis (AL), Adding Insult to Injury," 1 published in a recent issue of The American Journal of Medicine. Crees and Stockerl-Goldstein mentioned that ". . . overlap creates unique challenges in caring for patients with AL which are further compounded by the immunosuppressive nature of anti-plasma cell therapies, the need for frequent clinical assessments and the exclusion of AL patients from initial COVID-19 vaccine trials. . ." 1 We agree that managing COVID-19 and administering COVID-19 immunization to patients with underlying disease can be difficult. The immunodeficiency aspect of AL, as well as the need to use immunosuppressive drugs, is frequently a problem in COVID and vaccine management. A fundamental concern is if there is a danger associated with management or vaccination.

Treatment is essential if there is an infection, regardless of whether or not the patient has previously used immunomodulatory drugs. Similarly, during a pandemic, everybody must practice illness prevention. The clinical issue is usually about the drug/vaccine's efficacy and safety. Because of the compromised immune nature of the AL disease, reduced medication and vaccination efficacy is likely. If there is excellent pre-vaccine planning and post-vaccination monitoring, vaccination should be no difficulty. The quick increase in blood viscosity following immunization, similar to that of a cancer patient on chemotherapy, may pose a safety risk. 2 Because the AL patient may have a background high blood viscosity, 3 and increased blood viscosity is a biological process after COVID-19 vaccination 4 or COVID-19 infection, 5 

COVID-19 and light chain amyloidosis, adding insult to injury

COVID-19 vaccination in oncology patients receiving chemotherapy

Plasma cell myeloma, hyperviscosity and amyloidosis associated with a serum IgG3 lambda and urinary excretion of two fragments related to the variable portion of lambda light chains

Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19

Blood viscosity of COVID-19 patient: a preliminary report

Authorship: Both authors contributed equally − Substantial contributions to study conception and design, acquisition of data, analysis and interpretation of data; Drafting the article or revising it critically for important intellectual content; and Final approval of the version of the article to be published. Requests for reprints should be addressed to Rujitika Mungmunpuntipantip